NEW YORK ─ Avalon GloboCare said Monday that it has entered a strategic partnership with Beijing-based genetic testing services provider GensKey Medical Technology to codevelop and commercialize point-of-care antibody and PCR tests for SARS-CoV-2.
Both the antibody- and PCR-based tests have received the CE-IVD mark and are pending US Food and Drug Administration Emergency Use Authorization, Avalon said.
Financial and other terms of the deal were not disclosed.